<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760665</url>
  </required_header>
  <id_info>
    <org_study_id>KAPEDIS</org_study_id>
    <nct_id>NCT04760665</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae</brief_title>
  <acronym>KAPEDIS</acronym>
  <official_title>Randomized, Superiority, Double Blind Controlled With Placebo, Clinical Trial, to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Klebsiella Pneumoniae Carbapenemase (KPC)-Producing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mikrobiomik Healthcare Company S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections caused by carbapenemase-producing Enterobacteriaceae are frequent and often&#xD;
      associated with high rates of mortality. Colonized patients are at increased risk of&#xD;
      infection for these microorganisms. Moreover, they can act as a reservoir facilitating the&#xD;
      transmission to other patients. To date, decolonization strategies with antibiotics have not&#xD;
      obtained convincing results. For that reason our main objective is to investigate the&#xD;
      efficacy of fecal microbiota transplantation (FMT) for selective intestinal decolonization of&#xD;
      patients colonized by KPC-producing Klebsiella pneumoniae (Kp-KPC) at 30 days after FMT. Our&#xD;
      hypothesis is that FMT is effective and safe for selective intestinal decolonization in&#xD;
      patients colonized by Kp-KPC. The design of the study is a randomized, superiority, double&#xD;
      blind controlled with placebo clinical trial.&#xD;
&#xD;
      The main variable is the percentage of patients with intestinal decolonization at 30 days&#xD;
      after FMT in intention to treat population (all randomized patients). Decolonization will be&#xD;
      considered as the abscence of isolation of Kp-KPC in culture from rectal swab together with&#xD;
      the abscence of detection of carbapenemase by mean of polymerase chain reaction.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To evaluate the safety of FMT.&#xD;
&#xD;
        -  To determine if FMT is associated with decrease in the amount of bacteria at 7 days&#xD;
           after FMT and 30 days after FMT.&#xD;
&#xD;
        -  To evaluate if FMT is associated with persistent intestinal decolonization at 3 months&#xD;
           after intervention.&#xD;
&#xD;
        -  To study if FMT is associated with decrease in the incidence of Kp-KPC infections at 3&#xD;
           months after intervention.&#xD;
&#xD;
        -  To evaluate if FMT is associated with decrease in mortality due to Kp-KPC infections at&#xD;
           3 months after intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decolonization</measure>
    <time_frame>30 days after treatment.</time_frame>
    <description>Percentage of patients with intestinal decolonization after receiving oral capsules of FMT or placebo in intention to treat population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse effects</measure>
    <time_frame>90 days after treatment.</time_frame>
    <description>Percentage of patients with adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial load</measure>
    <time_frame>7 days and 30 days after treatment.</time_frame>
    <description>Amount of KPC-producing Klebsiella pneumoniae (Kp-KPC) after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent intestinal decolonization</measure>
    <time_frame>90 days after treatment.</time_frame>
    <description>Persistence of intestinal decolonization 90 days after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections caused by Kp-KPC</measure>
    <time_frame>90 days after treatment.</time_frame>
    <description>Percentage of patients with infections caused by Kp-KPC after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days after treatment.</time_frame>
    <description>Percentage of patients died after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Carbapenemase-producing Enterobacteriaceae Infection</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbiota transplantation</intervention_name>
    <description>Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; = 18 years.&#xD;
&#xD;
          -  Signature of the informed consent by the patient or legally designated person&#xD;
&#xD;
          -  Absence of active infection by carbapenemase-type KPC-producing Klebsiella pneumoniae&#xD;
             at the time of assessment as well as in the month prior to inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal situation, or estimated life expectancy of less than 3 months&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Intolerance or inability to take oral medication at the time of assessment&#xD;
&#xD;
          -  History of aspiration or dysphagia&#xD;
&#xD;
          -  Patients with a history of colectomy, colostomy or ileostomy&#xD;
&#xD;
          -  Patients who are receiving or have received antibiotics in the month prior to the&#xD;
             inclusion assessment&#xD;
&#xD;
          -  Neutrophil count less than 500 cells / mm3&#xD;
&#xD;
          -  Anticipation of the use of myelosuppressive treatment (eg. dexamethasone, chemotherapy&#xD;
             against to solid tumors or prior to transplantation of hematopoietic progenitories)&#xD;
             within 30 days after inclusion in the study&#xD;
&#xD;
          -  Hematopoietic stem cell transplantation in the month prior to inclusion in the study&#xD;
&#xD;
          -  Presence of clinical signs of mucositis&#xD;
&#xD;
          -  Forecast of major abdominal surgical intervention in the month following inclusion in&#xD;
             the study&#xD;
&#xD;
          -  Patients with a Gianella Score&gt; 12 points&#xD;
&#xD;
          -  History of having received decolonization guidelines in the previous 3 months&#xD;
&#xD;
          -  Severe food allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan José Castón Osorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángela Cano Yuste, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan José Castón Osorio, MD</last_name>
    <phone>00 34 671 59 60 70</phone>
    <email>juanjoco2005@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Luque</last_name>
    <phone>(+34) 671 596 070</phone>
    <email>uicec@imibic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jose Caston Osorio, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fecal microbiota transplantation</keyword>
  <keyword>Klebsiella pneumoniae</keyword>
  <keyword>carbapenemase</keyword>
  <keyword>intestinal colonization</keyword>
  <keyword>decolonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Klebsiella Infections</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publishing the results in a journal.</ipd_time_frame>
    <ipd_access_criteria>Upon request to uicec@imibic.org</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

